

Theranostics, a New Innovative Approach to Cancer Treatment

✓ **Dr. Hee-Seung Henry Bom**
Chonnam National University Hospital

✓ **Dr. Ilhan Yim**
Korea Institute of Radiological & Medical Sciences

Theranostics, a portmanteau of “therapeutic” and “diagnostics”, represents a significant advance in precision medicine, particularly in the field of oncology. This innovative approach combines diagnostic imaging and targeted therapy to treat diseases like cancer with high specificity and efficacy. By using molecular targets to guide treatment, theranostics offers a personalized medical treatment pathway, tailoring therapy to an individual’s specific disease characteristics.

1. Introduction to Theranostics

Definition and Concept

Theranostics is a cutting-edge precision medicine technology that integrates therapy and diagnosis into a single, real-time process. The term “theranostics” is a combination of “therapeutic” and “diagnostics”, reflecting its dual capability. This approach allows for the simultaneous diagnosis and treatment of diseases, particularly cancer, by targeting specific molecular markers in diseased cells. Theranostics utilizes advanced imaging techniques to identify disease locations and then administers targeted therapy, all within the same framework, leading to highly precise and effective treatments. [1]

Importance in Precision Medicine

Theranostics is crucial to the evolution of precision medicine, as it enables highly individualized treatment plans based on the unique molecular characteristics of a patient’s disease. Unlike traditional methods that apply a one-size-fits-all approach, theranostics targets specific cellular markers that can vary widely among patients, even with the same type of cancer. This allows for more effective treatments while minimizing side effects and unnecessary exposure to ineffective therapies. Furthermore, the ability to monitor treatment efficacy in real-time enables immediate adjustments, ensuring optimal outcomes for patients.

2. Key Characteristics of Theranostics

Precision Medicine Approach

Theranostics exemplifies precision medicine by focusing on the accurate targeting of small molecular markers present on disease cells. For example, in prostate cancer, theranostics targets prostate-specific membrane antigen (PSMA) on cancer cells. The expression of these markers can differ among patients, so theranostics allows for treatment strategies to be tailored precisely to each individual's condition, maximizing the effectiveness of the therapy.

Personalized Treatment Plans

Theranostics enables personalized treatment by identifying and targeting specific disease markers unique to each patient. This personalized approach ensures that therapies are only administered to those who will benefit from them, reducing the risk of ineffective treatments. For instance, if a patient's cancer cells lack a particular target, the corresponding therapy would be ineffective, highlighting the need for personalized treatment plans.

Real-time Monitoring of Treatment Efficacy

A significant advantage of theranostics is the capability to monitor treatment efficacy in real-time. Once a therapeutic agent is administered, its impact can be observed through nuclear medicine imaging. This allows clinicians to assess the extent of disease reduction and adjust subsequent treatments accordingly, ensuring that therapies remain effective and are tailored to the patient's evolving condition.

Role of Delivery Vehicles for Targeting

The delivery of therapeutic agents to specific disease sites is a critical component of theranostics. This is typically achieved using delivery vehicles, such as ligands or antibodies, which guide the therapeutic agents directly to the disease cells. The precision of these delivery vehicles ensures that the treatment is focused on the diseased cells, minimizing collateral damage to healthy tissue and enhancing the overall effectiveness of the therapy.

Use of Different Radioisotopes for Diagnosis and Treatment

Theranostics involves the use of different radioisotopes for diagnostic imaging and therapeutic purposes. For diagnosis, isotopes that emit positrons, such as those used in positron emission tomography (PET), help accurately identify the presence and extent of disease within the body. For example, Gallium-68 (Ga-68) is commonly used for PET imaging. For treatment, isotopes that emit therapeutic radiation, such as alpha or beta particles, are used to destroy the targeted cells. Lutetium-177 (Lu-177) is a frequently used therapeutic isotope that delivers radiation directly to cancer cells, sparing surrounding healthy tissues.




Figure 1. Concept of Theranostics: The Process of Delivering Radioisotopes to Targets

3. Current Applications and Effective Diseases

Theranostics in Neuroendocrine Tumors [2]

Neuroendocrine tumors (NETs) are rare cancers that originate from neuroendocrine cells found in various organs such as the gastrointestinal tract and lungs. These tumors are often diagnosed incidentally or at advanced stages due to their slow-growing nature and lack of early symptoms. Traditionally, surgery has been the primary treatment for NETs, but in cases where the disease is inoperable or has metastasized, theranostics offers a promising alternative.

Theranostics targets somatostatin receptors, which are highly expressed on NET cells. Using radiolabeled somatostatin analogs, such as DOTATOC or DOTATATE labeled with Ga-68, clinicians can precisely locate these tumors through PET imaging. For treatment, the same analogs can be labeled with therapeutic isotopes like Lu-177 or Yttrium-90 (Y-90) to deliver targeted radiation to the tumor cells. This approach has shown significant improvements in patient outcomes, as demonstrated by the NETTER-1 trial, making theranostics a powerful tool in managing NETs.




Figure 2. Case of Neuroendocrine Tumor Showing the Therapeutic Effects of Theranostics

Application in Prostate Cancer [3]

Prostate cancer is one of the most common cancers among men, particularly in developed countries. Conventional treatments, including surgery, radiation therapy, hormone therapy, and chemotherapy, may be less effective in advanced or hormone-resistant cases.

Theranostics has revolutionized the treatment of prostate cancer by targeting PSMA, which is overexpressed in prostate cancer cells. PSMA-targeted PET imaging, using Ga-68, enables the precise detection of prostate cancer and its metastases. For treatment, PSMA-targeted compounds labeled with therapeutic isotopes such as Lu-177 or Actinium-225 (Ac-225) deliver targeted radiation to cancer cells. Clinical trials like the VISION trial have shown that this approach significantly improves survival rates and quality of life for patients with advanced, metastatic prostate cancer.




Figure 3. Therapeutic Effects of Alpha-Emitting Ac-225 PSMA Theranostics *

* A case of theranostics in a patient with metastatic prostate cancer using Actinium-225 (Ac-225) PSMA. The patient, whose cancer had spread throughout the body and did not respond to hormone therapy, showed significant improvement after theranostics treatment. The metastatic lesions (black spots) that were spread throughout the body became much less pronounced, and the serum PSA tumor marker levels were reduced by half.

Treatment of Thyroid Cancer

Thyroid cancer is the most frequently diagnosed cancer in South Korea, with a high survival rate when detected early. However, in cases of advanced or recurrent disease, especially among older patients or those with undifferentiated thyroid cancer, the prognosis is poorer.

Theranostics plays a vital role in managing thyroid cancer, particularly in cases where the disease has metastasized or recurred. The traditional treatment involves surgery followed by radioactive iodine therapy (I-131) to target residual cancer cells. In theranostics, diagnostic imaging with iodine isotopes such as I-123 or I-124 is used to locate metastatic sites, while I-131 is used for targeted therapy. This method is especially beneficial for patients with advanced thyroid cancer, offering a more effective treatment option than conventional therapies alone.




Figure 4. Case of Thyroid Cancer Showing the Therapeutic Effects of Theranostics

4. Comparison with Traditional Cancer Treatments

Limitations of Surgery, Chemotherapy, Radiation Therapy, and Other Conventional Methods [4]

Traditional cancer treatments, while effective in many cases, have several limitations. Surgery, the oldest form of cancer treatment, involves physically removing the tumor. However, it is often challenging to determine if all cancer cells have been removed, especially those that are microscopic and invisible during surgery. Additionally, surgery may not be feasible for tumors located in inoperable areas or for patients with advanced additional diseases.

Chemotherapy works by targeting rapidly dividing cells, a hallmark of cancer. However, it also affects healthy cells that divide rapidly, leading to significant side effects such as hair loss, fatigue, and immune suppression. Chemotherapy is not always effective, particularly for cancers that do not respond well to these drugs, and can cause damage to normal tissues, limiting the dosage that can be safely administered.

Radiation therapy, which involves directing high-energy radiation at the tumor, is another common treatment. However, even with advanced techniques, it is challenging to target the tumor precisely without affecting surrounding healthy tissues. This can result in damage to critical organs and structures near the cancer site, limiting the effectiveness of the treatment and increasing the risk of side effects.

Other treatments, such as localized therapies (e.g., laser or ultrasound) and emerging approaches like gene therapy and immunotherapy, also have limitations. Localized therapies may not reach tumors deep within the body, and gene therapy, while promising, still faces challenges in safety and efficacy. Immunotherapy, which leverages the body's immune system to fight cancer, often needs to be combined with other treatments to achieve optimal results and is not effective for all patients.

Advantages of Theranostics Over Conventional Treatments

Theranostics offers several advantages over these conventional treatments by addressing many of their limitations. One of the key benefits of theranostics is its ability to provide real-time monitoring and adjustment of treatment. This allows for a more dynamic

and responsive treatment approach, where the effectiveness of the therapy can be continuously assessed and adjusted as needed. This reduces the risk of overtreatment or undertreatment, which are common issues in traditional cancer therapies.

Moreover, theranostics specifically targets cancer cells while sparing normal tissues, significantly reducing the side effects typically associated with chemotherapy and radiation therapy. For example, in contrast to traditional chemotherapy which affects all rapidly dividing cells, theranostics delivers therapeutic radiation directly to the cancer cells via targeted radiolabeled agents. This precise targeting minimizes damage to healthy cells and tissues, leading to fewer side effects and better patient outcomes.

Another major advantage of theranostics is its ability to treat tumors that are difficult to reach with surgery or traditional localized therapies. Since theranostics agents can be delivered systemically, they can target tumors throughout the body, regardless of their location. This is particularly beneficial for patients with metastatic cancer, where the disease has spread to multiple sites.

Finally, theranostics integrates diagnosis and treatment into a single approach, enabling a more efficient and streamlined treatment process. By combining imaging and therapy, theranostics ensures that the treatment is not only targeted but also continuously guided by accurate, up-to-date diagnostic information. This integration leads to better treatment planning and potentially improved survival outcomes, especially in cancers that have limited treatment options with conventional methods.

5. Global Research Trends

International Developments in Theranostics

Theranostics has rapidly emerged as a transformative approach in the field of oncology, with significant developments occurring globally. Europe and the United States have been at the forefront of these advancements, with a strong focus on developing radiopharmaceuticals that combine diagnostic and therapeutic capabilities. This integrated approach allows for precise targeting and treatment of various cancers, particularly those that are difficult to treat with conventional methods.

In Europe, Germany has been a leader in theranostics, particularly in the development of PSMA-targeted radiopharmaceuticals for prostate cancer. The United States has also made significant strides, with the U.S. Food and Drug Administration (FDA) approving several theranostic agents, including those for the treatment of NETs and prostate cancer. These international efforts have led to the commercialization of various theranostic products that are now widely used in clinical practice.

Success Stories and Ongoing Clinical Trials

Theranostics has seen numerous success stories, particularly in the treatment of cancers that have traditionally been challenging to manage. For example, the NETTER-1 trial, an international phase 3 clinical trial, demonstrated the effectiveness of Lu-177 DOTATATE in treating patients with advanced neuroendocrine tumors. This trial showed that patients treated with Lu-177 DOTATATE had a significantly longer progression-free survival compared to those receiving standard care, highlighting the potential of theranostics to improve patient outcomes.

In prostate cancer, the VISION trial has been a landmark study, demonstrating the efficacy of Lu-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer. The trial results showed that this theranostic approach not only extended overall survival but also improved the quality of life for patients who had limited treatment options.

Ongoing clinical trials continue to explore the potential of theranostics in various cancers. For instance, trials are investigating the use of Ac-225 in combination with PSMA-targeted therapy for prostate cancer, as well as the use of radiolabeled somatostatin

analogs in other neuroendocrine tumors. These trials aim to refine and expand the applications of theranostics, potentially offering new hope for patients with difficult-to-treat cancers.

Prominent Examples of Theranostics Products

Several theranostics products have been developed and are now in use, with some becoming standard of care in specific cancer treatments. In the field of NETs, Lu-177 DOTATATE (Lutathera) has become a widely used therapy following its success in clinical trials. This radiopharmaceutical specifically targets somatostatin receptors, which are overexpressed in many neuroendocrine tumors, allowing for targeted treatment with minimal impact on surrounding healthy tissue.

In prostate cancer, Ga-68 PSMA PET/CT imaging and Lu-177 PSMA therapy have revolutionized the diagnosis and treatment of advanced cases. These products enable precise imaging and targeted radiotherapy, significantly improving outcomes for patients with metastatic prostate cancer.

Other examples include radiolabeled iodine (I-131) for the treatment of thyroid cancer, which has been a cornerstone of theranostics for decades. This approach has been particularly successful in treating patients with metastatic or recurrent thyroid cancer, offering a targeted therapy option that is both effective and widely accessible.

6. Theranostics in the Asia-Pacific Region

Current State of Development and Use

The Asia-Pacific region is witnessing a growing interest in theranostics, with countries like South Korea, Japan, and Singapore taking the lead in both research and clinical applications. South Korea is at the forefront, integrating theranostics into its healthcare system through significant investments in research infrastructure, ongoing clinical trials, and the development of new radiopharmaceuticals by companies such as FutureChem and CellBion. These efforts are supported by a strong regulatory framework and a robust healthcare system, positioning South Korea as a competitive player on the global stage.

Japan, with its long-standing expertise in nuclear medicine, is also making substantial contributions to the field. The country is focused on advancing theranostics by developing novel radiopharmaceuticals, refining imaging techniques, and establishing clinical guidelines. Japan's active participation in international collaborations and clinical trials further cements its leadership role in the region.

Singapore is emerging as a key hub for theranostics research in Southeast Asia, characterized by advanced facilities and a strong emphasis on translational research that bridges laboratory discoveries with clinical applications. The country's strategic location and advanced healthcare infrastructure, coupled with proactive government support for research initiatives, have positioned Singapore as a significant player in the Asia-Pacific region.

Challenges in Regulation, Standardization, and Implementation

Despite the progress made, the Asia-Pacific region faces several challenges in the widespread adoption of theranostics. One of the primary challenges is the lack of standardized regulatory frameworks across the region. [5] While countries like South Korea, Japan, and Singapore have established regulations for the use of radiopharmaceuticals, many other countries in the region are still developing these frameworks. This lack of standardization can hinder the development and approval of new theranostic agents, as companies must navigate a complex and varied regulatory landscape.

Another challenge is the high cost of theranostics, which can be a significant barrier to access in many countries. The development, production, and administration of theranostic agents require advanced technology and specialized expertise, which can drive up costs. In developing countries, the lack of infrastructure and funding further exacerbates this issue, limiting the availability of these treatments to a small subset of patients.

Finally, the implementation of theranostics requires a high level of expertise in both nuclear medicine and oncology. The shortage of trained professionals in these fields across the region poses a significant challenge to the widespread adoption of theranostics. To address this, there is a need for greater investment in education and training programs, as well as international collaboration to share knowledge and resources.

7. Educational and Research Initiatives

Training Programs for Nuclear Medicine Specialists

The advancement of theranostics in the Asia-Pacific region requires a strong foundation in education and training, particularly for nuclear medicine specialists. As theranostics involves the use of sophisticated imaging techniques and radiopharmaceuticals, it is crucial that healthcare professionals are adequately trained to handle these technologies. Currently, the training programs for nuclear medicine specialists vary significantly across the region, ranging from two to four years, depending on the country. For instance, South Korea and Taiwan offer four-year training programs, while other countries like Vietnam and Myanmar have shorter programs or lack specialized training.

Given the complexity of theranostics, there is a pressing need to enhance these training programs to include specific modules on theranostics techniques, safety protocols, and the latest developments in radiopharmaceuticals. Moreover, the establishment of specialized training centers across the region could help bridge the knowledge gap and ensure that nuclear medicine specialists are well-prepared to implement theranostics in clinical practice.

Need for Standardized Theranostics Training in Asia-Pacific

One of the major challenges facing the Asia-Pacific region is the lack of standardized training in theranostics. The varying levels of expertise and the absence of a unified curriculum hinder the effective implementation of theranostics across different countries. To address this issue, there is a need for a standardized training program that can be adopted region-wide. Such a program would ensure that all nuclear medicine specialists receive a consistent level of education and are equipped with the necessary skills to perform theranostics.

Standardization could also facilitate better collaboration between countries in the region, as specialists would be trained under similar protocols and standards. This would enhance the exchange of knowledge and expertise, leading to more effective and coordinated efforts in the development and application of theranostics.

Potential for Collaborative Research and Development in the Region

The Asia-Pacific region holds significant potential for collaborative research and development in theranostics. With countries like South Korea, Japan, and Singapore leading the way in research, there is an opportunity to establish regional partnerships that can drive innovation and accelerate the development of new theranostic agents. Collaborative research efforts could focus on areas such as the development of novel radiopharmaceuticals, optimization of imaging techniques, and exploration of new therapeutic targets.

Moreover, collaboration can extend beyond research to include joint clinical trials, shared access to advanced facilities, and coordinated efforts to address regulatory challenges. By pooling resources and expertise, the region can overcome the barriers to theranostics development and ensure that cutting-edge treatments are available to a broader population. Establishing a network of research institutions across the Asia-Pacific could also create a robust pipeline for theranostics innovations, positioning the region as a leader in this emerging field.

8. Conclusion and Future Directions

Summary of Theranostics' Impact on Cancer Treatment

Theranostics has revolutionized the approach to cancer treatment by integrating diagnosis and therapy into a single, cohesive process. This technology has demonstrated significant advantages over traditional treatments, offering personalized, targeted therapies that minimize side effects and improve patient outcomes. In particular, theranostics has shown great promise in the treatment of cancers such as NETs, prostate cancer, and thyroid cancer, where traditional methods often fall short. The ability to monitor treatment efficacy in real-time and adjust therapies accordingly has set theranostics apart as a transformative tool in oncology.

Importance of Regional Collaboration in Research and Education

As theranostics continues to evolve, regional collaboration in research and education will be crucial for its successful implementation across the Asia-Pacific. Given the diverse levels of development and expertise in the region, collaboration can help standardize practices, share knowledge, and optimize resources. Joint educational initiatives, such as standardized training programs and shared research platforms, will ensure that nuclear medicine specialists are equipped to handle the complexities of theranostics.

Collaboration can also lead to the development of region-specific solutions that address the unique challenges faced by different countries. By working together, the Asia-Pacific region can build a strong foundation for the widespread adoption of theranostics, ensuring that all patients benefit from the latest advancements in cancer treatment.


Proposal for Establishing a Theranostics-focused Educational and Research Organization (FANMB Academy)

To facilitate these collaborative efforts, the establishment of a theranostics-focused educational and research organization, such as the proposed Fellow of Asia Nuclear Medicine Board (FANMB) Academy, would be highly beneficial. The FANMB Academy could serve as a central hub for training, research, and collaboration in theranostics across the region. It would bring together nuclear medicine specialists, researchers, and industry partners to foster innovation, share best practices, and develop new standards for theranostics.

The academy could also play a key role in organizing regional conferences, workshops, and online courses to disseminate the latest research findings and clinical practices. By building a strong network of professionals dedicated to advancing theranostics, the FANMB Academy could drive the region's leadership in this field and ensure that the Asia-Pacific remains at the forefront of global developments in cancer treatment.

Opportunities for Asian-Pacific Leadership in Theranostics Development

The Asia-Pacific region is well-positioned to become a global leader in theranostics development. With a growing number of research institutions, a commitment to innovation, and a strategic focus on precision medicine, the region has the potential to shape the future of cancer treatment. By capitalizing on these strengths and fostering collaboration across borders, the Asia-Pacific can lead the way in the development and implementation of theranostics.

Investing in education, research, and infrastructure will be key to realizing this potential. By establishing centers of excellence, such as the proposed FANMB Academy, and creating opportunities for collaboration and knowledge exchange, the region can ensure that it remains at the cutting edge of theranostics innovation. As a leader in this field, the Asia-Pacific can set new standards for cancer treatment, improving outcomes for patients not only in the region but around the world. 

References

- [1] Duan H, Iagaru A, Aparici CM. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. *Nanotheranostics*. 2022 Jan 1;6(1):103-117
- [2] Ichikawa Y, Kobayashi N, Takano S, Kato I, Endo K, Inoue T. Neuroendocrine tumor theranostics. *Cancer Sci*. 2022 Jun;113(6):1930-1938.
- [3] Kulkarni HR, Singh A, Langbein T, Schuchardt C, Mueller D, Zhang J, Lehmann C, Baum RP. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. *Br J Radiol*. 2018 Nov;91(1091):20180308
- [4] Types of Cancer Treatment. <https://www.cancer.gov/about-cancer/treatment/types> accessed 12th Aug, 2024
- [5] Perera M, Morris MJ. From Concept to Regulatory Drug Approval: Lessons for Theranostics. *J Nucl Med*. 2022 Dec;63(12):1793-1801

Disclaimer: The views expressed in this issue brief are those of the author and do not necessarily reflect the official position of RCARO. RCARO acknowledges that the content is based on the author's research and perspective, thus does not warrant its completeness or accuracy.

RCA Issue Brief Committee

Publication Advisors

- To be informed | Republic of Korea
- Huang Ping | China
- Shalendra Prasad | Fiji
- Khemphone Phaokhamkeo | IAEA

Editorial Advisors

- Prinath Dias | Sri Lanka
- Abdul Muin Abdul Rahman | Malaysia
- Perry Davy | New Zealand

Publisher

- RCA Regional Office



Call for Articles

RCA Issue Brief



📢 Call for *Issue Brief Papers*

– Insights on Nuclear Science and Technology in the RCA Region

RCA Newsletter also publishes the Issue Brief, dedicated to disseminating informative and analytical materials that provide in-depth insights into the peaceful uses of nuclear science and technology within the RCA region. We cordially invite contributions from experts, researchers, and RCA-related stakeholders to submit Issue Briefs that explore these topics. A standard format of an article is about 3,000–4000 words (10–12 pages of WORD document in English) accompanying several pictures/images related to the article. Relevant guidelines and article templates can be found [here](#). Please send us the article to djlee@caro.org.



R C A